TCR2 Therapeutics (TCRR) Reports Q1 Loss of $4.85
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
TCR2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 4:07 PM EDTInitiated Phase 1/2 clinical trial for TC-210, TCR2s lead product candidate targeting mesothelin expressing solid tumorsOn track to file an IND for TCR2s lead hematology product candidate, TC-110, in patients with CD19+ non-Hodgkin lymphomas and leukemias in 2H 2019Recent publication in Nature Communications and scientific presentations highlight advantages of the Companys TRuC-T cell platformEstablished occupancy of manufacturing suite at Cell and Gene Therapy Catapult in the UK
CAMBRIDGE, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq:... More
